Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Ramipril 2.5 mg/5 ml oral solution. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2612. 2012 Authors' conclusions Ramipril oral solution is recommended as an option for use within NHS Wales for:
- Treatment of hypertension.
- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:
- manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral
vascular disease);
- diabetes with at least one cardiovascular risk factor.
- Treatment of renal disease:
- incipient glomerular diabetic nephropathy as defined by the presence of macroalbuminuria;
- manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one
cardiovascular risk factor;
- manifest glomerular non diabetic nephropathy as defined by macroproteinuria = 3 g/day.
- Treatment of symptomatic heart failure.
- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial
infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction. Indexing Status Subject indexing assigned by CRD MeSH Administration, Oral; Cardiovascular Diseases; Heart Failure; Hypertension; Kidney Diseases; Ramiprils Language Published English Country of organisation Wales English summary An English language summary is available. Address for correspondence All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Email: AWTTC@wales.nhs.uk AccessionNumber 32012000874 Date abstract record published 26/11/2012 |